HK1061246A1 - Intermediates for the preparation of anti-thrombotic 4h-cyclopenta-1,3- dioxol derivatives - Google Patents

Intermediates for the preparation of anti-thrombotic 4h-cyclopenta-1,3- dioxol derivatives

Info

Publication number
HK1061246A1
HK1061246A1 HK04104367.3A HK04104367A HK1061246A1 HK 1061246 A1 HK1061246 A1 HK 1061246A1 HK 04104367 A HK04104367 A HK 04104367A HK 1061246 A1 HK1061246 A1 HK 1061246A1
Authority
HK
Hong Kong
Prior art keywords
cyclopenta
thrombotic
intermediates
preparation
dioxol
Prior art date
Application number
HK04104367.3A
Other languages
English (en)
Inventor
David Hardern
Anthony Ingall
Brian Springthorpe
Paul Willis
Simon Guile
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26663448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1061246(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from SE9804211A external-priority patent/SE9804211D0/xx
Priority claimed from SE9901271A external-priority patent/SE9901271D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1061246A1 publication Critical patent/HK1061246A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/40Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing only non-condensed rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK04104367.3A 1998-12-04 2002-02-19 Intermediates for the preparation of anti-thrombotic 4h-cyclopenta-1,3- dioxol derivatives HK1061246A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9804211A SE9804211D0 (sv) 1998-12-04 1998-12-04 Novel compounds
SE9901271A SE9901271D0 (sv) 1999-04-09 1999-04-09 Novel compounds
HK02101198.6A HK1039933B (zh) 1998-12-04 2002-02-19 新的三唑並(4,5-d)嘧啶化合物

Publications (1)

Publication Number Publication Date
HK1061246A1 true HK1061246A1 (en) 2004-09-10

Family

ID=26663448

Family Applications (3)

Application Number Title Priority Date Filing Date
HK02101198.6A HK1039933B (zh) 1998-12-04 2002-02-19 新的三唑並(4,5-d)嘧啶化合物
HK04104367.3A HK1061246A1 (en) 1998-12-04 2002-02-19 Intermediates for the preparation of anti-thrombotic 4h-cyclopenta-1,3- dioxol derivatives
HK04104617.1A HK1061684A1 (en) 1998-12-04 2004-06-28 Intermediates for the preparation of certain triazolopyrimidines as p2t antagonists

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK02101198.6A HK1039933B (zh) 1998-12-04 2002-02-19 新的三唑並(4,5-d)嘧啶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK04104617.1A HK1061684A1 (en) 1998-12-04 2004-06-28 Intermediates for the preparation of certain triazolopyrimidines as p2t antagonists

Country Status (36)

Country Link
US (12) US6525060B1 (fr)
EP (5) EP1386909A1 (fr)
JP (4) JP4202607B2 (fr)
KR (4) KR100776484B1 (fr)
CN (1) CN1128801C (fr)
AR (3) AR023920A1 (fr)
AT (3) ATE261970T1 (fr)
AU (1) AU766618B2 (fr)
BR (1) BRPI9915883B8 (fr)
CA (1) CA2351709C (fr)
CY (3) CY1110501T1 (fr)
CZ (3) CZ295234B6 (fr)
DE (4) DE69915675T4 (fr)
DK (3) DK1135391T3 (fr)
EG (1) EG24814A (fr)
ES (3) ES2318081T3 (fr)
FR (1) FR11C0016I2 (fr)
HK (3) HK1039933B (fr)
HU (2) HU228589B1 (fr)
ID (1) ID29927A (fr)
IL (6) IL143232A0 (fr)
LT (1) LTC1135391I2 (fr)
LU (1) LU91819I2 (fr)
MY (1) MY121867A (fr)
NO (2) NO319806B1 (fr)
NZ (1) NZ511778A (fr)
PL (1) PL201283B1 (fr)
PT (2) PT1135391E (fr)
RU (3) RU2317990C2 (fr)
SA (1) SA99200848B1 (fr)
SI (3) SI1135391T1 (fr)
SK (1) SK286007B6 (fr)
TR (1) TR200101567T2 (fr)
TW (1) TWI229674B (fr)
WO (1) WO2000034283A1 (fr)
ZA (1) ZA200104094B (fr)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
SE9903290D0 (sv) * 1999-09-15 1999-09-15 Astra Pharma Prod Novel compounds
SE9904129D0 (sv) 1999-11-15 1999-11-15 Astra Pharma Prod Novel compounds
SE9904377D0 (sv) * 1999-12-01 1999-12-01 Astra Pharma Prod Pharmaceutical combinations
AR028110A1 (es) * 2000-06-02 2003-04-23 Astrazeneca Ab Nuevo proceso
GB0013488D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Chemical compound
GB0013407D0 (en) * 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7115585B2 (en) 2000-08-21 2006-10-03 Inspire Pharmaceuticals, Inc. Compositions for treating epithelial and retinal tissue diseases
US7452870B2 (en) 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US6897201B2 (en) 2000-08-21 2005-05-24 Inspire Pharmaceuticals, Inc. Compositions and methods for the treatment of glaucoma or ocular hypertension
SE0101932D0 (sv) * 2001-05-31 2001-05-31 Astrazeneca Ab Pharmaceutical combinations
US7435724B2 (en) 2002-02-27 2008-10-14 Inspire Pharmaceutical, Inc. Degradation-resistant mononucleoside phosphate compounds
CN100471842C (zh) 2003-07-24 2009-03-25 安斯泰来制药有限公司 喹诺酮衍生物或其盐
SE0400873D0 (sv) * 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
SE0401001D0 (sv) 2004-03-31 2004-03-31 Astrazeneca Ab Chemical process
JPWO2007020935A1 (ja) * 2005-08-17 2009-02-26 小野薬品工業株式会社 P2y12受容体および/またはp2y14受容体ブロッカーを含有してなる疼痛治療剤
TWI391378B (zh) 2006-03-16 2013-04-01 Astellas Pharma Inc 喹啉酮衍生物或其製藥學上可被容許之鹽
GB0615620D0 (en) 2006-08-05 2006-09-13 Astrazeneca Ab A process for the preparation of optically active intermediates
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
WO2008024044A1 (fr) * 2006-08-21 2008-02-28 Astrazeneca Ab Compositions pour administration orale comprenant un dérivé de triazolo [4, 5] pyrimidine
WO2008054795A2 (fr) 2006-10-31 2008-05-08 Janssen Pharmaceutica, N.V. Dérivés de triazolopyrimidine convenant comme antagonistes du récepteur p2y12 de l'adp
TWI496776B (zh) * 2007-11-15 2015-08-21 Astrazeneca Ab 製備(3aR,4S,6R,6aS)-6-胺基-2,2-二甲基四氫-3aH-環戊并[d][1,3]二氧雜環戊烯-4-醇之純非對映異構性之二苯甲醯-L-酒石酸鹽之方法
UA100864C2 (uk) * 2007-12-03 2013-02-11 Астразенека Аб Спосіб лікування або запобігання аневризмі черевної аорти
TWI389913B (zh) * 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
SG196805A1 (en) * 2008-09-09 2014-02-13 Astrazeneca Ab A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
WO2010043721A1 (fr) 2008-10-17 2010-04-22 Oryzon Genomics, S.A. Inhibiteurs d’oxydases et leur utilisation
EP2389362B1 (fr) 2009-01-21 2019-12-11 Oryzon Genomics, S.A. Dérivés de phénylcyclopropylamine et leur utilisation médicale
ES2605625T3 (es) * 2009-07-27 2017-03-15 Auspex Pharmaceuticals, Inc. Moduladores de ciclopropilo del receptor P2Y12
EP2305376A1 (fr) 2009-09-23 2011-04-06 Lonza Ltd. Procédé et catalyseur pour l'hydrogénation catalytique de composés de nitro aromatiques et hétéro-aromatiques
WO2011035941A1 (fr) 2009-09-25 2011-03-31 Oryzon Genomics S.A. Inhibiteurs de déméthylase-1 spécifique de la lysine et leur utilisation
US8946296B2 (en) 2009-10-09 2015-02-03 Oryzon Genomics S.A. Substituted heteroaryl- and aryl-cyclopropylamine acetamides and their use
BR112012013365A2 (pt) 2009-12-03 2016-03-01 Astrazeneca Ab co-cristal do composto, método para preparar um co-cristal do composto, composição farmacêutica, uso de um co-cristal do composto, e, método de tratamento de complicações trombóticas arteriais
EP2633857B1 (fr) 2009-12-23 2015-08-12 ratiopharm GmbH Forme de dosage solide pharmaceutique de ticagrelor et de l'acide acétylsalicylique
EP2536695A1 (fr) 2010-02-16 2012-12-26 Actavis Group Ptc Ehf Procédés améliorés pour préparer un intermédiaire de ticagrelor, la 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
WO2011106573A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase utilisés dans le traitement et la prévention de maladies et de troubles associés à hepadnaviridae
US9616058B2 (en) 2010-02-24 2017-04-11 Oryzon Genomics, S.A. Potent selective LSD1 inhibitors and dual LSD1/MAO-B inhibitors for antiviral use
PL2560947T3 (pl) 2010-04-19 2017-04-28 Oryzon Genomics, S.A. Inhibitory demetylazy specyficznej dla lizyny i ich zastosowanie
CA2796504A1 (fr) 2010-04-20 2011-10-27 Actavis Group Ptc Ehf Nouveau procede de preparation de derives de phenylcyclopropylamine par utilisation de nouveaux intermediaires
AU2011273101A1 (en) 2010-06-30 2013-01-17 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
EP2598480B1 (fr) 2010-07-29 2019-04-24 Oryzon Genomics, S.A. Dérivés de cyclopropylamine utiles en tant qu'inhibiteurs de lsd1
NO2598482T3 (fr) 2010-07-29 2018-09-01
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012063126A2 (fr) 2010-11-09 2012-05-18 Actavis Group Ptc Ehf Procédés améliorés de préparation de (3ar,4s,6r,6as)-6-amino-2,2-diméthyltétrahdro-3ah-cyclopenta[d] [1,3]-dioxol-4-ol pur et son matériau de départ clé
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
US20130317220A1 (en) * 2010-12-20 2013-11-28 Actavis Group Ptc Ehf NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
EP3981395A1 (fr) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour des troubles myéloprolifératifs
CN102653539B (zh) * 2011-03-01 2014-09-17 秦引林 一种抗血小板聚集化合物及其药物组合
WO2012138981A2 (fr) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. Nouveaux intermédiaires et procédés pour la préparation du ticagrelor
CN102731510B (zh) * 2011-04-07 2015-12-16 博瑞生物医药(苏州)股份有限公司 替卡格雷的衍生物、制备方法及其药物用途
CZ2011229A3 (cs) 2011-04-19 2012-08-15 Zentiva, K.S. Opticky aktivní soli (3aR,4S,6R,6aS)-6-amino-2,2-dimethyltetrahydro-3aH-cyklopenta-[d][1,3]dioxol-4-olu a zpusob jejich prípravy
PT2707363E (pt) * 2011-05-13 2016-01-07 Astrazeneca Ab Um processo para a preparação de carbamato de benzilo [(3as,4r,6s,6ar)-6-hidroxi-2,2-dimetiltetrahidro-3ah-ciclopenta[d][1,3]dioxol]-4-il] e de intermediários
WO2012156531A2 (fr) * 2011-05-19 2012-11-22 Oryzon Genomics, S.A. Inhibiteurs de la lysine déméthylase destinés au traitement de maladies ou états inflammatoires
US20140296255A1 (en) * 2011-05-19 2014-10-02 Oryzong Genomics, S.A. Lysine demethylase inhibitors for thrombosis and cardiovascular diseases
CA2836394A1 (fr) 2011-06-01 2012-12-06 Astrazeneca Ab Nouveaux co-cristaux de ticagrelor
EP2721018A1 (fr) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Procédé amélioré de préparation de dérivés de cyclopentanamine et de leurs intermédiaires
CN102924457A (zh) * 2011-08-12 2013-02-13 上海恒瑞医药有限公司 三唑并嘧啶类衍生物、其制备方法及其用途
EP2570405A1 (fr) 2011-09-14 2013-03-20 LEK Pharmaceuticals d.d. Synthèse de composés de triazolopyrimidines
PL2755957T4 (pl) 2011-09-14 2017-05-31 Lek Pharmaceuticals D.D. Synteza związków triazolopirymidynowych
EP3736265A1 (fr) 2011-10-20 2020-11-11 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropylamine comme inhibiteurs de lsd1
KR102079406B1 (ko) 2011-10-20 2020-02-19 오리존 지노믹스 에스.에이. Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
EP2586773A1 (fr) 2011-10-27 2013-05-01 LEK Pharmaceuticals d.d. Synthèse de composés de type triazolopyrimidine
ES2665546T3 (es) * 2011-10-27 2018-04-26 Lek Pharmaceuticals D.D. Síntesis de compuestos de triazolopirimidina
EP2589587A1 (fr) 2011-11-04 2013-05-08 Chemo Ibérica, S.A. Synthèse de cyclopropanes à substitution azote
AU2012343928A1 (en) 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
EP2607355A1 (fr) * 2011-12-23 2013-06-26 LEK Pharmaceuticals d.d. Synthèse de triazolopyrimidines
US9278972B2 (en) 2011-12-23 2016-03-08 Lek Pharmaceuticals D.D. Synthesis of triazolopyrimidine compounds
EP2628721A1 (fr) 2012-02-20 2013-08-21 LEK Pharmaceuticals d.d. Synthèse de l'acide 2-(3,4-difluorophényl) cyclopropanecarboxylique
EP2644590A1 (fr) 2012-03-30 2013-10-02 LEK Pharmaceuticals d.d. Synthèse de dérivés et sels de 2-(3,4-difluorophényl) cyclopropanamine
CN104603098B (zh) 2012-03-30 2016-06-29 桑多斯股份公司 2-(3,4-二氟苯基)环丙胺衍生物和盐的合成
EP2834247A4 (fr) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr Préparation de ticagrelor
WO2013163892A1 (fr) * 2012-05-02 2013-11-07 Sunshine Lake Pharma Co., Ltd. Nouveaux composés de triazolopyrimidine et leur procédé de préparation
CN102659815B (zh) * 2012-05-04 2013-07-17 开原亨泰制药股份有限公司 一种制备选择性抗凝血药替卡格雷及其中间体的方法
EP2666771A1 (fr) 2012-05-24 2013-11-27 LEK Pharmaceuticals d.d. Synthèse de dérivés aminocyclopentanétriols
ITMI20121142A1 (it) * 2012-06-28 2013-12-29 Chemo Iberica Sa Processo chemoenzimatico per la produzione di fenil ciclopropilammine
EP2867235A1 (fr) * 2012-06-29 2015-05-06 Zentiva K.S. Nouvelles formes pharmaceutiques solides de (1s,2s,3r,5s)-3-[7-[(1r,2s)-2-(3,4difluorophényl)cyclopropylamino]-5-(propylthio)-3h-[1,2,3]triazolo[4,5-d]pyrimidin-3yl]-5-(2-hydroxyéthoxy)cyclopentane-l,2-diol
US9284320B2 (en) 2012-07-04 2016-03-15 Lek Pharmaceuticals D.D. Ticagrelor adducts with divalent metal salts
CN103626743B (zh) * 2012-08-23 2018-06-08 广东东阳光药业有限公司 替卡格雷的新型中间体及其制备方法
CN102875537A (zh) * 2012-09-10 2013-01-16 常州制药厂有限公司 一种新的抗血栓药物的制备方法
CZ2012705A3 (cs) 2012-10-16 2014-04-23 Zentiva, K.S. Pevná orální farmaceutická formulace obsahující ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
IN2012MU03723A (fr) 2012-12-31 2015-07-10 Megafine Pharma P Ltd
CN104045620B (zh) * 2013-03-12 2017-05-10 博瑞生物医药(苏州)股份有限公司 一种替卡格雷中间体的制备方法
CZ307217B6 (cs) 2013-03-14 2018-04-04 Zentiva, K.S. Zlepšený způsob výroby a nové intermediáty syntézy ticagreloru
IN2013MU01111A (fr) * 2013-03-25 2015-05-01 Glenmark Generics Ltd
ITMI20130487A1 (it) 2013-03-29 2014-09-30 Chemo Res S L Alchilazione selettiva di ciclopentilalcoli
CN104098553B (zh) 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
WO2014170026A1 (fr) 2013-04-18 2014-10-23 Zentiva, K.S. Ticagrelor amorphe stabilisé
EP2813216A1 (fr) 2013-06-10 2014-12-17 Zentiva, a.s. Ticagrelor amorphe stabilisé
CN104230818B (zh) * 2013-06-06 2018-01-12 郝聪梅 替卡格雷中间体的改进制备方法
EP2816043A1 (fr) 2013-06-21 2014-12-24 LEK Pharmaceuticals d.d. Particules Ticagrelor sphériques
WO2014206187A1 (fr) 2013-06-24 2014-12-31 苏州明锐医药科技有限公司 Procédé de préparation du ticagrelor et de ses intermédiaires
CN104250251B (zh) * 2013-06-25 2017-05-17 上海京新生物医药有限公司 一种替格瑞洛的制备方法
WO2015001489A1 (fr) 2013-07-01 2015-01-08 Ranbaxy Laboratories Limited Compositions pharmaceutiques de ticagrélor
CZ2013866A3 (cs) 2013-11-08 2015-05-20 Zentiva, K.S. Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru
WO2015110952A1 (fr) 2014-01-21 2015-07-30 Wockhardt Limited Compositions pharmaceutiques orales solides comprenant du ticagrelor ou un sel de ce dernier
CN103992323B (zh) * 2014-04-18 2017-03-29 南通常佑药业科技有限公司 一种替格瑞洛的制备方法
WO2015162630A1 (fr) 2014-04-25 2015-10-29 Anlon Chemical Research Organization Nouveaux procédés de préparation de triazolo[4,5-d]-pyrimidines, dont le ticagrelor, via de nouveaux intermédiaires et une nouvelle voie de synthèse
DE102014108210A1 (de) 2014-06-11 2015-12-17 Dietrich Gulba Rodentizid
US10011605B2 (en) 2014-06-18 2018-07-03 Flamma Spa Process for the preparation of triazolo[4,5-D] pyrimidine cyclopentane compounds
CN105272985B (zh) * 2014-06-24 2017-11-21 珠海联邦制药股份有限公司 三唑并[4,5‑d]嘧啶化合物及其合成方法、用途、组合物
WO2016001851A1 (fr) * 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Préparation de ticagrélor
WO2016050867A1 (fr) 2014-10-01 2016-04-07 Medimmune Limited Anticorps à ticagrelor et procédés de leur utilisation
WO2016116942A1 (fr) 2015-01-20 2016-07-28 Anlon Chemical Research Organization Nouveaux composés pharmaceutiques comprenant du ticagrélor avec des sels d'aspirine
CN105985346B (zh) * 2015-03-06 2019-10-18 苏州朗科生物技术股份有限公司 一种新的替格瑞洛化合物制备方法及其中间体化合物
US9789087B2 (en) 2015-08-03 2017-10-17 Thomas Jefferson University PAR4 inhibitor therapy for patients with PAR4 polymorphism
CN105237540B (zh) * 2015-09-21 2017-10-03 南京正大天晴制药有限公司 一种替格瑞洛有关物质的制备方法、检测方法及用途
US20190002471A1 (en) 2016-01-05 2019-01-03 Amneal Pharmaceuticals Company Gmbh Crystalline Form Of Ticagrelor
TR201601835A2 (tr) 2016-02-12 2017-08-21 Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇
US20170296666A1 (en) 2016-04-18 2017-10-19 Amneal Pharmaceuticals Company Gmbh Stable Pharmaceutical Composition Of Amorphous Ticagrelor
AU2017253367B2 (en) 2016-04-21 2020-04-16 Astrazeneca Ab Orally disintegrating tablets
WO2018038265A1 (fr) * 2016-08-26 2018-03-01 田辺三菱製薬株式会社 Composé hétérocyclique azoté bicyclique
US10905691B2 (en) 2016-09-09 2021-02-02 Université de Liège Use of triazolo(4,5-d)pyrimidine derivatives for prevention and treatment of bacterial infection
ES2731658T3 (es) 2016-09-09 2019-11-18 Univ Liege Derivados triazolo(4,5-d)pirimidina para uso en la prevención y tratamiento de infección bacteriana
CN107814772A (zh) * 2017-11-24 2018-03-20 常州沃腾化工科技有限公司 4,6‑二氯‑5‑氨基‑2‑丙硫基嘧啶酯的精制方法
EP3527571A1 (fr) * 2018-02-14 2019-08-21 Université de Liège Dérivés de pyrimidine pour la prévention et le traitement d'infections bactériennes
EP3829547A1 (fr) 2018-07-27 2021-06-09 KRKA, d.d., Novo mesto Composition pharmaceutique de ticagrélor
CN109761785A (zh) * 2019-02-16 2019-05-17 安徽诺全药业有限公司 一种(1r,2r)-2-(3,4-二氟苯基)环丙烷羧酸的合成方法
GB201910656D0 (en) * 2019-07-25 2019-09-11 Univ Liege New use of triazolo(4,5-d)Pyrimidine deerivatives
EP3919497A1 (fr) 2020-06-04 2021-12-08 Zaklady Farmaceutyczne Polpharma S.A. Procédé de préparation de ticagrelor
CN112876485A (zh) * 2021-01-25 2021-06-01 郭丽伟 一种用于治疗子宫平滑肌高频率强直性收缩相关疾病的化合物
EP4070658A1 (fr) 2021-04-06 2022-10-12 BIORoxx GmbH Utilisation de composés anticoagulants comme rodenticides
WO2023213198A1 (fr) * 2022-05-04 2023-11-09 华东师范大学 Utilisation d'un composé cyclique fusionné aromatique en tant qu'activateur de trek-1 et composition pharmaceutique et analgésique le contenant

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3106578A (en) 1960-09-16 1963-10-08 Smith Kline French Lab Nu-phenethyl-2-phenylcyclopropylamine derivatives
SE329623B (fr) 1967-06-08 1970-10-19 C F Boehringer Soehne Gmbh
DE1670265A1 (de) 1967-08-25 1971-01-28 Boehringer Mannheim Gmbh 2-Amino-Adenosinderivate und Verfahren zu deren Herstellung
CH558137A (de) 1971-05-17 1975-01-31 Ciba Geigy Ag Mittel zur beeinflussung des pflanzenwachstums.
US4016204A (en) * 1975-10-31 1977-04-05 Nelson Research & Development Company Method of synthesis of trans-2-phenylcyclopropylamine
US4543255A (en) 1984-05-10 1985-09-24 Southern Research Institute Carbocyclic analogs of purine 2'-deoxyribofuranosides
US4742064A (en) 1985-09-10 1988-05-03 Regents Of The University Of Minnesota Antiviral carbocyclic analogs of xylofuranosylpurines
DK175131B1 (da) 1988-01-20 2004-06-14 Univ Minnesota 4-(9H-Purin-9-yl)-2-cyclopentenylcarbinoler, farmaceutiske præparater indeholdende forbindelserne samt mellemprodukter derfor
WO1990006671A2 (fr) 1988-12-12 1990-06-28 Palese Peter M Procedes et compositions pour la prophylaxie et le traitement d'infections dues au virus de l'hepatite b
US5110933A (en) 1989-11-13 1992-05-05 Board Of Regents Of Oklahoma State University Salts of 3-azabicyclo[3.3.1]nonanes as antiarrhythmic agents, and precursors thereof
US5652366A (en) 1990-09-25 1997-07-29 Rhone-Poulenc Rorer Pharmaceuticals Inc. DI (1R)-(-)camphosulfonic acid) salt, preparation thereof and use thereof
WO1992012718A1 (fr) 1991-01-23 1992-08-06 Gensia, Inc. Inhibiteurs de l'adenosine-kinase
EP0579643A1 (fr) 1991-04-06 1994-01-26 FISONS plc Analogues d'atp
EP0521463A3 (en) 1991-07-04 1993-04-14 Hoechst Aktiengesellschaft Substituted cyclic cycloalkyltriols, process, intermediates for their preparation and their use as antiviral and antiparasitic agents
FI101150B (fi) 1991-09-09 1998-04-30 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi
US5817660A (en) 1991-12-06 1998-10-06 Hoechst Marion Roussel, Inc. Trans cyclopentanyl purine analogs useful as immunosuppressants
US5338725A (en) 1992-06-30 1994-08-16 The Research Foundation Of The State University Of New York Anti-aggregatory agents for platelets
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
NZ261159A (en) 1993-02-10 1997-06-24 Astra Pharma Prod Atp analogue and pharmaceutical compositions thereof
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
US5620676A (en) 1994-03-08 1997-04-15 The United States Of America As Represented By The Department Of Health And Human Services Biologically active ATP analogs
US5831099A (en) 1995-03-10 1998-11-03 The United States Of America As Represented By The Secretary Of The Army Compounds of 1,5-disubstituted-3,7 diaza bicyclo 3.3.0! octanes and products containing the same
US5712258A (en) 1995-03-23 1998-01-27 The Trustees Of The University Of Pennsylvania Inotropic ADP and ATP analogues and their pharmaceutical compositions
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
ATE217010T1 (de) 1995-07-11 2002-05-15 Astrazeneca Ab Inhibitoren der plättchenaggregation
WO1997009330A1 (fr) 1995-09-01 1997-03-13 Hokuriku Seiyaku Co., Ltd. Cristal d'hydrate et son procede de preparation
US6790626B2 (en) 1995-11-21 2004-09-14 Euroscreen S.A. Human pyrimidine receptor
US5948437A (en) 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
ATE213245T1 (de) * 1996-12-20 2002-02-15 Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JPH10258654A (ja) 1997-03-18 1998-09-29 Delta Tsuuring:Kk リクライニングシート
SE9702775D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
TW530058B (en) * 1997-07-22 2003-05-01 Astra Pharma Prod Triazolo [4,5-d]pyrimidine compounos and their use and process for preparation
SE9702773D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9702772D0 (sv) 1997-07-22 1997-07-22 Astra Pharma Prod Novel compounds
SE9704709D0 (sv) 1997-12-17 1997-12-17 Astra Ab Pharmaceutically active compounds
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
EP1063231B1 (fr) 1999-06-21 2005-05-11 Yamamoto Chemicals, Inc. Composés polyméthiniques, procédé pour leur préparation et leur utilisation
SE9903759D0 (sv) 1999-10-18 1999-10-18 Astra Ab Pharmaceutically active compounds
MXPA02004795A (es) 1999-11-12 2005-07-01 Biogen Inc Antagonistas del receptor de adenosina y los metodos para producir y utilizar los mismos.
GB0013407D0 (en) 2000-06-02 2000-07-26 Astrazeneca Ab Forms of a chemical compound
US7040429B2 (en) 2001-10-10 2006-05-09 Invacare Corporation Wheelchair suspension
EP1455758A1 (fr) 2001-12-21 2004-09-15 Pfizer Products Inc. Formulations d'azithromycine directement compressibles
TWI482772B (zh) 2006-08-21 2015-05-01 Astrazeneca Ab 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物
SG196805A1 (en) 2008-09-09 2014-02-13 Astrazeneca Ab A process for preparing [1s- [1-alpha, 2-alpha, 3-beta (1s*, 2r*) 5-beta] ] -3- [7- [2- (3, 4-dif luorophenyl) -cyclopropylamino] - 5- (propylthio) -3h-1, 2, 3-triazolo [4, 5-d] pyrimidin-3-yl] -5- (2- hydroxyethoxy) cyclopentane-1, 2-diol and to its intermediates
EP2536695A1 (fr) 2010-02-16 2012-12-26 Actavis Group Ptc Ehf Procédés améliorés pour préparer un intermédiaire de ticagrelor, la 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine
AU2011273101A1 (en) 2010-06-30 2013-01-17 Actavis Group Ptc Ehf Novel processes for the preparation of phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor
US20130317220A1 (en) 2010-12-20 2013-11-28 Actavis Group Ptc Ehf NOVEL PROCESSES FOR PREPARING TRIAZOLO[4, 5-d]PYRIMIDINE DERIVATIVES AND INTERMEDIATES THEREOF
WO2012138981A2 (fr) 2011-04-06 2012-10-11 Teva Pharmaceutical Industries Ltd. Nouveaux intermédiaires et procédés pour la préparation du ticagrelor
EP2721018A1 (fr) 2011-06-15 2014-04-23 Actavis Group Ptc Ehf Procédé amélioré de préparation de dérivés de cyclopentanamine et de leurs intermédiaires
AU2012343928A1 (en) 2011-11-30 2014-05-29 Actavis Group Ptc Ehf Novel crystalline form of ticagrelor and process for the preparation thereof
EP2834247A4 (fr) 2012-04-05 2016-03-30 Reddys Lab Ltd Dr Préparation de ticagrelor
WO2014083139A1 (fr) 2012-11-29 2014-06-05 Actavis Group Ptc Ehf Nouvelle forme amorphe de ticagrelor
IN2012MU03723A (fr) 2012-12-31 2015-07-10 Megafine Pharma P Ltd
WO2014118808A2 (fr) 2013-02-04 2014-08-07 Hetero Research Foundation Dispersion solide de ticagrelor
CN104098553B (zh) 2013-04-10 2017-11-28 江苏恒瑞医药股份有限公司 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法
EP3004113A2 (fr) 2013-06-04 2016-04-13 Dr. Reddy's Laboratories Ltd. Préparation de ticagrélor
WO2016001851A1 (fr) 2014-07-02 2016-01-07 Dr. Reddy's Laboratories Limited Préparation de ticagrélor
CN112402423A (zh) 2015-01-27 2021-02-26 阿斯利康(瑞典)有限公司 治疗或预防具有心肌梗塞病史的患者的动脉粥样硬化血栓形成事件的方法

Also Published As

Publication number Publication date
EP1386921A1 (fr) 2004-02-04
AU2016500A (en) 2000-06-26
EP2322513A3 (fr) 2011-08-24
ATE261970T1 (de) 2004-04-15
US6525060B1 (en) 2003-02-25
SA99200848B1 (ar) 2006-11-04
CN1128801C (zh) 2003-11-26
DE69915675T4 (de) 2012-08-30
CA2351709A1 (fr) 2000-06-15
DK1135391T3 (da) 2004-06-28
HU228589B1 (en) 2013-04-29
IL198040A0 (en) 2009-12-24
ES2216623T3 (es) 2004-10-16
ES2318081T3 (es) 2009-05-01
KR100776484B1 (ko) 2007-11-28
ATE513816T1 (de) 2011-07-15
SI1386917T1 (sl) 2011-09-30
US20140296258A1 (en) 2014-10-02
HUP0105081A3 (en) 2004-11-29
BRPI9915883B1 (pt) 2015-08-18
KR100822602B1 (ko) 2008-04-16
CZ300373B6 (cs) 2009-05-06
USRE46276E1 (en) 2017-01-17
KR20010081054A (ko) 2001-08-25
CZ300280B6 (cs) 2009-04-08
RU2007133926A (ru) 2009-03-20
AU766618B2 (en) 2003-10-23
KR20060091056A (ko) 2006-08-17
US20030144305A1 (en) 2003-07-31
RU2317990C2 (ru) 2008-02-27
US20130109702A1 (en) 2013-05-02
US20060025590A1 (en) 2006-02-02
CZ20011962A3 (cs) 2001-11-14
US20130072503A1 (en) 2013-03-21
CY2011005I1 (el) 2014-04-09
DK1386921T3 (da) 2009-03-23
KR100742924B1 (ko) 2007-07-25
JP5415383B2 (ja) 2014-02-12
SI1135391T1 (en) 2004-08-31
US6974868B2 (en) 2005-12-13
RU2012121883A (ru) 2013-11-27
EP1386921B1 (fr) 2008-12-24
US20100069408A1 (en) 2010-03-18
TWI229674B (en) 2005-03-21
JP2008266345A (ja) 2008-11-06
EP2322513A2 (fr) 2011-05-18
DE69915675T2 (de) 2005-02-17
KR20070007971A (ko) 2007-01-16
EG24814A (en) 2010-09-21
NZ511778A (en) 2003-10-31
NO20012725D0 (no) 2001-06-01
DE69915675D1 (de) 2004-04-22
IL143232A0 (en) 2002-04-21
IL198040A (en) 2015-06-30
HK1039933B (zh) 2004-10-08
AR072756A2 (es) 2010-09-22
IL143232A (en) 2008-12-29
PT1386921E (pt) 2009-02-23
ID29927A (id) 2001-10-25
CY2011005I2 (el) 2014-04-09
US20120165348A1 (en) 2012-06-28
EP1135391B1 (fr) 2004-03-17
EP1386909A1 (fr) 2004-02-04
LTPA2011004I1 (lt) 2022-04-11
SK7492001A3 (en) 2002-01-07
KR100764417B1 (ko) 2007-10-05
LU91819I2 (fr) 2011-08-01
NO319806B1 (no) 2005-09-19
NO20012725L (no) 2001-07-31
CN1334816A (zh) 2002-02-06
CA2351709C (fr) 2010-04-06
CZ295234B6 (cs) 2005-06-15
SI1386921T1 (sl) 2009-04-30
JP5043749B2 (ja) 2012-10-10
HK1061684A1 (en) 2004-09-30
DE122011100004I1 (de) 2011-09-08
AR023920A1 (es) 2002-09-04
PL201283B1 (pl) 2009-03-31
FR11C0016I1 (fr) 2011-07-08
EP1386917B1 (fr) 2011-06-22
MY121867A (en) 2006-02-28
PT1135391E (pt) 2004-07-30
JP2011016831A (ja) 2011-01-27
HUP0105081A2 (hu) 2002-05-29
HUS1300048I1 (hu) 2017-03-28
EP1386917A1 (fr) 2004-02-04
HK1039933A1 (en) 2002-05-17
AR058967A2 (es) 2008-03-05
EP1135391A1 (fr) 2001-09-26
NO2011007I2 (no) 2012-07-09
US7250419B2 (en) 2007-07-31
PL348724A1 (en) 2002-06-03
FR11C0016I2 (fr) 2012-03-16
BR9915883A (pt) 2001-08-21
SK286007B6 (sk) 2008-01-07
RU2593201C2 (ru) 2016-08-10
US20070265282A1 (en) 2007-11-15
JP4202607B2 (ja) 2008-12-24
IL183969A0 (en) 2009-02-11
US20080214812A1 (en) 2008-09-04
LTC1135391I2 (lt) 2022-04-11
BRPI9915883B8 (pt) 2021-05-25
CY1110501T1 (el) 2015-04-29
US20150152111A1 (en) 2015-06-04
WO2000034283A1 (fr) 2000-06-15
DE69940171D1 (de) 2009-02-05
KR20070086540A (ko) 2007-08-27
TR200101567T2 (tr) 2001-12-21
NO2011007I1 (no) 2011-06-06
ES2366902T3 (es) 2011-10-26
JP2002531567A (ja) 2002-09-24
DK1386917T3 (da) 2011-08-29
JP2007084551A (ja) 2007-04-05
ZA200104094B (en) 2002-08-19
CY1111759T1 (el) 2015-10-07
IL210398A0 (en) 2011-03-31
IL169013A (en) 2015-10-29
IL183969A (en) 2011-03-31
ATE418547T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
HK1061246A1 (en) Intermediates for the preparation of anti-thrombotic 4h-cyclopenta-1,3- dioxol derivatives
HUP0100779A3 (en) Novel derivatives of 3,3-diphenylpropylamines
AU4922499A (en) Trioxane derivatives
HUP0101375A3 (en) Novel cephalotaxane derivatives, process for their preparation and intermediates
IL146579A0 (en) Process for the preparation of herbicidal derivatives
AU7902400A (en) Method for the preparation of 5-carboxyphthalide
AU1379900A (en) Novel substituted phenyloxazolidone derivatives
PL342060A1 (en) Derivatives of 1,3,4-oxadiaxolone
AU7972200A (en) Process for the preparation of urea
AU6123099A (en) Process for the preparation of amine derivatives
AU5762099A (en) The preparation of (n)-substituted-hydroxycycloalkylamine derivatives
AU2466700A (en) Process for the preparation of urea
AU4659199A (en) Process for the preparation of urea
AU1651001A (en) Difluoromethyltriazolone compounds, use of the same and intermediates for the production thereof
GB2363605B (en) Process for the preparation of alpha-aminoketone derivatives
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
AU2829700A (en) Processes for the preparation of alpha-aminoketones
AU7752698A (en) Method for the synthesis of anti-microbial hydroxybenzoats
AU4997199A (en) Process for the synthesis of benzopyran derivatives
AU1130901A (en) Method for the preparation of 5-carboxyphthalide
AU6028900A (en) Method for the preparation of urea
AU6228499A (en) Tetrahydropyridopyridine derivatives and intermediates for producing the same
AU1974800A (en) Process for the preparation of strobilurin intermediates
AU6001299A (en) Dithiol derivatives
AU6000299A (en) Processes for the preparation of 4-substituted benzopyran derivatives